Scholar Rock Holding (SRRK) stock has drawn investor attention after a recent move in its share price, with the company’s Nasdaq listing closing at $47.33 and showing mixed short and longer term return figures.

For context, Scholar Rock Holding’s recent 1-day share price return of 0.81% and 7-day share price return of 7.13% sit alongside a slightly weaker 30-day share price return, while its 1-year and 3-year total shareholder returns point to strong longer term momentum.

If you are weighing Scholar Rock Holding against other high-growth healthcare names, it could be a good moment to see what else is setting up in the rare disease and biotech space through 40 healthcare AI stocks

With Scholar Rock Holding showing strong multi year total returns but mixed recent performance and trading below some analyst targets, the key question is whether the stock is still undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 14.1% Undervalued

Scholar Rock Holding's most followed narrative pegs fair value at $55.07 against the recent $47.33 close, putting the focus firmly on its SMA franchise and broader neuromuscular pipeline.

Growing use of SMN targeted therapies in SMA, now representing roughly US$5b in annual global sales and an estimated 35,000 treated patients, creates a sizable pool of patients where apitegromab may be used as an add on muscle targeted therapy, which could influence long term revenue potential.

Want to see what is underneath that add on therapy angle? The narrative leans on aggressive revenue build out, margin expansion and a rich future earnings multiple. The exact mix of assumptions matters.

Behind the $55.07 fair value, the narrative links high projected revenue growth, a shift toward industry level profit margins and a premium multiple on future earnings, all discounted using a 7.1% rate. Those ingredients, together with analyst agreement that the stock is trading below both their targets and the internal fair value estimate, form the core case that Scholar Rock Holding is undervalued on this framework.

Result: Fair Value of $55.07 (UNDERVALUED)

However, the apitegromab story for Scholar Rock Holding still hinges on regulatory timing and real world functional outcomes, either of which could quickly challenge this valuation setup.

Next Steps

If this Scholar Rock Holding story feels finely balanced between promise and concern, now is a good time to review the underlying data and form your own stance. You can start with 3 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Scholar Rock Holding?

If you stop with Scholar Rock Holding, you could miss other setups that fit your style, so take a few minutes to scan fresh ideas with the Simply Wall St Screener.

• Chase potential upside in quality companies trading below intrinsic estimates by running the 45 high quality undervalued stocks and comparing their fundamentals side by side.
• Strengthen your income stream by focusing on companies that combine yield with resilience through the 8 dividend fortresses.
• Dial back portfolio risk by filtering for companies with steadier profiles using the 65 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.